Latest news for  (OTC:USUTF) Stock

Redburn Atlantic analyst Hamilton Faber maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Buy and raises the price target from $740 to $760.

News

Price Target

Analyst Ratings

NFLX

Redburn Atlantic Maintains Buy on Netflix, Raises Price Target to $760

Oppenheimer analyst Brian Schwartz maintains Agilysys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) with a Outperform and raises the price target from $100 to $120.

AGYS

Oppenheimer Maintains Outperform on Agilysys, Raises Price Target to $120

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Baird analyst Andrew Wittmann downgraded the rating for Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) from Outperform to Neutral, while increasing the price target from $750 to $775. Cintas shares gained 5.4% to settle at $758.97 on Thursday. See how other analysts view this stock. <a href="https://www.benzinga.com/quote/CTAS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Arun Viswanathan downgraded Sealed Air Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>) from Outperform to Sector Perform, while cutting the price target from $43 to $40. Sealed Air shares fell 1.3% to close at $36.39 on Thursday. <a href="https://www.benzinga.com/quote/SEE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stephens &amp; Co. analyst Jim Salera downgraded the rating for Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) from Overweight to Equal-Weight, but raised the price target from $36 to $37.5. Chuy&#8217;s shares climbed 47.8% to close at $37.34 on Thursday. <a href="https://www.benzinga.com/quote/CHUY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Tien-Tsin Huang downgraded WNS (Holdings) Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) from Overweight to Neutral and maintained a price target of $60. WNS shares dipped 3.5% to close at $57.95 on Thursday. <a href="https://www.benzinga.com/quote/WNS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Janney Montgomery Scott analyst Timothy Coffey downgraded the rating for Banner Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) from Buy to Neutral. Banner shares fell 1.4% to close at $58.49 on Thursday. <a href="https://www.benzinga.com/quote/BANR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39858280/how-to-earn-500-a-month-from-verizon-stock-ahead-of-q2-earnings-report">How To Earn $500 A Month From Verizon Stock Ahead Of Q2 Earnings Report</a></li>
</ul>

Downgrades

Markets

Trading Ideas

BANR

CHUY

CTAS

This Sealed Air Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Keybanc analyst Jason Celino maintains Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) with a Overweight and lowers the price target from $200 to $171.

PCTY

Keybanc Maintains Overweight on Paylocity Holding, Lowers Price Target to $171

Trading To Commence On Split-Adjusted Basis On August 5, 2024 Under Symbol "VATE"

Stock Split

VATE

Innovate Announces 1-for-10 Reverse Stock Split Effective August 2, 2024

JP Morgan analyst Joseph Greff downgrades Host Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) from Neutral to Underweight and lowers the price target from $20 to $18.

JP Morgan Downgrades Host Hotels & Resorts to Underweight, Lowers Price Target to $18

Keybanc analyst Jeffrey Hammond maintains Hayward Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) with a Overweight and lowers the price target from $17 to $16.

HAYW

Keybanc Maintains Overweight on Hayward Holdings, Lowers Price Target to $16

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies. `
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">LegalZoom.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>)</h3>
<ul>
<li>LegalZoom.com will report its financial results for the second quarter on Wednesday, Aug. 7, after the closing bell. The company's stock fell around 22% over the past month and has a <a href="https://www.benzinga.com/quote/LZ">52-week low of $5.33</a>.</li>
<li>RSI Value: 27.98</li>
<li>LZ Price Action: Shares of LegalZoom.com fell 1.2% to close at $6.39 on Thursday.</li>
<li><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071924&amp;t=be2bearmibe3na1">Benzinga Pro's real-time newsfeed</a> alerted to latest LZ news.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="680" height="727" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/19065532/Screenshot-2024-07-19-at-4.25.09-PM.png" alt="" class="wp-image-445268" style="width:435px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/19065532/Screenshot-2024-07-19-at-4.25.09-PM.png 680w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/19065532/Screenshot-2024-07-19-at-4.25.09-PM-281x300.png 281w" sizes="(max-width: 680px) 100vw, 680px" /></a></figure>
<h3 class="wp-block-heading">Grab Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On July 17, Jefferies analyst Thomas Chong maintained Grab Hldgs with a Buy rating and lowered the price target from $5 to $4.7. The company's stock fell around 7% over the past five days. It <a href="https://www.benzinga.com/quote/GRAB">has a 52-week low</a> of $2.90.</li>
<li>RSI Value: 27.61</li>
<li>GRAB Price Action: Shares of Grab Holdings fell 2.3% to close at $3.41 on Thursday.</li>
<li>Benzinga Pro's charting tool helped identify the <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071924&amp;t=be2bearmibe3na1">trend in Grab Holdings stock</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="688" height="749" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/19065611/Screenshot-2024-07-19-at-4.25.59-PM.png" alt="" class="wp-image-445274" style="width:459px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/19065611/Screenshot-2024-07-19-at-4.25.59-PM.png 688w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/19065611/Screenshot-2024-07-19-at-4.25.59-PM-276x300.png 276w" sizes="(max-width: 688px) 100vw, 688px" /></a></figure>
<h3 class="wp-block-heading">Expion360 Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>)</h3>
<ul>
<li>On May 14, Expion360 posted a first-quarter loss of 31 cents per share. &#8220;In the first quarter of 2024 we fortified our position as a leader in premium LiFePO4 batteries with next generation battery product launches and new technologies,&#8221; said Brian Schaffner, Chief Executive Officer of Expion360. The company's stock dipped around 20% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/XPON">low of $0.83</a>.</li>
<li>RSI Value: 24.50</li>
<li>XPON Price Action: Shares of Expion360 fell 6.4% to close at $0.85 on Thursday.</li>
<li>Benzinga Pro's signals feature notified of a <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071924&amp;t=be2bearmibe3na1">potential breakout in XPON shares</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="657" height="739" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/19070428/Screenshot-2024-07-19-at-4.34.20-PM.png" alt="" class="wp-image-445308" style="width:417px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/19070428/Screenshot-2024-07-19-at-4.34.20-PM.png 657w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/19070428/Screenshot-2024-07-19-at-4.34.20-PM-267x300.png 267w" sizes="(max-width: 657px) 100vw, 657px" /></a></figure>
Read More: 
<a href="https://www.benzinga.com/news/earnings/24/07/39853970/dow-plunges-over-500-points-following-unexpected-surge-in-us-jobless-claims">Dow Plunges Over 500 Points Following Unexpected Surge In US Jobless Claims</a>

Long Ideas

Pre-Market Outlook

GRAB

XPON

Top 3 Industrials Stocks That May Rocket Higher In Q3

Keybanc analyst Alex Markgraff maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Overweight and raises the price target from $23 to $25.

HOOD

Keybanc Maintains Overweight on Robinhood Markets, Raises Price Target to $25

Evercore ISI Group analyst Vijay Kumar maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a In-Line and lowers the price target from $425 to $410.

ISRG

Evercore ISI Group Maintains In-Line on Intuitive Surgical, Lowers Price Target to $410

JMP Securities analyst Trevor Cranston maintains AG Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) with a Market Outperform and raises the price target from $7.5 to $8.5.

MITT

JMP Securities Maintains Market Outperform on AG Mortgage IT, Raises Price Target to $8.5

JP Morgan analyst Joseph Greff downgrades Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) from Neutral to Underweight and announces $120 price target.

JP Morgan Downgrades Choice Hotels Intl to Underweight, Announces $120 Price Target

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>), ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company's HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC). &nbsp;
The published manuscript, titled "Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth," reports the work of Dr. Mira Jung, Professor of Radiation Medicine&nbsp;at Georgetown University Medical Center, and Dr. Scott Grindrod, Shuttle Pharma's Principal Scientist, and was published in PLOS ONE, a peer-reviewed open access journal published by the Public Library of Science (PLOS).

Biotech

General

SHPH

Shuttle Pharma's Selective HDAC Inhibitor Exhibits Ataxia-Telangiectasia Mutated Protein Activation And Modulation Of ER Expression Resulting In Growth Inhibition Of Estrogen Receptor Positive Breast Cancer Cells, As Reported In 'Public Library Of Science ONE'

JP Morgan analyst Anupam Rama upgrades AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) from Neutral to Overweight and raises the price target from $29 to $69.

Upgrades

ANAB

JP Morgan Upgrades AnaptysBio to Overweight, Raises Price Target to $69

BMO Capital analyst Keith Bachman maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Outperform and lowers the price target from $54 to $49.

BMO Capital Maintains Outperform on Dynatrace, Lowers Price Target to $49

Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) shares are trading lower after the company reported second-quarter&nbsp;2024 revenue of&nbsp;$5.833 billion,&nbsp;missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39856421/halliburton-announces-second-quarter-2024-results" rel="noreferrer noopener">consensus of&nbsp;$5.949 billion</a>.
Completion and Production revenue was&nbsp;$3.4 billion, flat Q/Q. Revenue growth from increased completion tool sales and stimulation activity abroad, as well as improved well-intervention services, was offset by lower stimulation and completion tool sales in the U.S. and decreased artificial lift services in North America.
Drilling and Evaluation revenue came in at $2.4 billion, flat Q/Q. Results benefitted from increased drilling services in Europe, North America, and Asia, higher wireline activity in the Western Hemisphere and Europe, and a rise in international testing services.
HAL&#8217;s North&nbsp;America&nbsp;revenue fell&nbsp;3%&nbsp;Q/Q to&nbsp;$2.5 billion&nbsp;due reduced pressure pumping services in U.S. land and lower activity in the Gulf of Mexico.
International revenue was&nbsp;$3.4 billion, an increase of&nbsp;3%&nbsp;Q/Q, with revenue from Latin America&nbsp;flat Q/Q, Europe/Africa&nbsp;+4% Q/Q,&nbsp;and Middle East/Asia&nbsp;+5% Q/Q.
Operating income stood at $1.032 billion (+5% Q/Q), with an operating margin of about 18% in the quarter.
EPS of $0.80 was <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">in line with the consensus.</a>
The company repurchased ~$250 million of its common stock during the quarter.
Operating cash flow stood at&nbsp;$1.1 billion&nbsp;for the quarter, and free cash flow was&nbsp;$800 million.
Jeff Miller, Chairman, President, and CEO, said, &#8220;In our international markets we see strong demand for Halliburton&#8217;s services, high activity levels, and equipment tightness across all major basins.&#8221;
Investors can gain exposure to the stock via VanEck Oil Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIH#NYSE">OIH</a>) and IShares U.S. Oil Equipment &amp; Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEZ#NYSE">IEZ</a>).
Price Action: HAL shares are down&nbsp;4.53%&nbsp;at&nbsp;$34.80 premarket&nbsp;at&nbsp;the last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Wikimedia Commons

Earnings

Equities

Large Cap

Buybacks

Movers

iShares Dow Jones US Oil Equipment & Services Index Fund

Halliburton's Q2 Revenue Miss Highlights Challenges In US Market, Despite International Gains

Acme United (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ACU#AMEX">ACU</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $0.94 by 15.96 percent. This is a 13.54 percent increase over earnings of $0.96 per share from the same period last year. The company reported quarterly sales of $55.42 million which missed the analyst consensus estimate of $56.54 million by 1.97 percent. This is a 3.92 percent increase over sales of $53.34 million the same period last year.

Acme United Q2 EPS $1.09 Beats $0.94 Estimate, Sales $55.42M Miss $56.54M Estimate

&nbsp;
<ul>
<li>Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysm</li>
<li>Altamira's SemaPhore&#x2122; nanoparticles delivering SOD2 mRNA successfully to mitochondria in aorta wall
<ul>
<li>Positive outcomes suggest potential use of treatment in management of small abdominal aortic aneurysm and prevention of ruptures &nbsp;&nbsp;&nbsp;</li>
</ul>
</li>
</ul>

CYTO

Altamira Therapeutics Publishes Preclinical Data For Treatment Of Abdominal Aortic Aneurysm With SOD2 mRNA Delivered By SemaPhore Nanoparticles

Management

Triumph Group Appoints Mike Boland COO

Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) ("Molina") announced today that the Florida Agency for Healthcare Administration (AHCA) has awarded a new Medicaid managed care contract to Molina's health plan subsidiary, Molina Healthcare of Florida, Inc. Under the contract award in Miami-Dade and Monroe Counties, Molina expects to serve approximately 90,000 Medicaid beneficiaries. The contract term is expected to commence on January 1, 2025, and to run through December 31, 2030.

Contracts

Molina Healthcare Awarded New Florida Medicaid Contract, Expects To Serve ~90,000 Medicaid Beneficiaries

SPDR S&P U.S. Utilities Select Sector UCITS ETF (Acc)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

News

Latest news for (OTC:USUTF) Stock